Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19198810 | 1.00 | SLC6A4 (0.41) | SLC6A4SLC6A3SLC6A2LMNACYP2C9 | |
| SCHEMBL19250236 | 0.86 | LMNA (0.34) | SLC6A4SLC6A3SLC6A2LMNACYP2C9 | |
| SCHEMBL8373572 | 0.82 | SLC6A4 (0.40) | SLC6A4SLC6A3SLC6A2LMNACYP2C9 | |
| SCHEMBL20975786 | 0.81 | OPRM1 (0.32) | — | |
| SCHEMBL7292734 | 0.80 | SLC6A4 (0.39) | SLC6A4SLC6A3SLC6A2LMNACYP2C9 | |
| Hydrochloric Acid SCHEMBL7291978 | 0.78 | SLC6A4 (0.38) | SLC6A4SLC6A3SLC6A2LMNACYP2C9 | |
| SCHEMBL19198739 | 0.77 | SLC6A4 (0.37) | SLC6A4SLC6A3SLC6A2LMNACYP2C9 | |
| SCHEMBL19194780 | 0.77 | — | — | |
| SCHEMBL19199513 | 0.77 | — | — | |
| SCHEMBL4743604 | 0.75 | LMNA (0.46) | SLC6A4SLC6A3SLC6A2LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-20120203004-A1 | PROCESS FOR THE SYNTHESIS OF ALKYL/ARALKYL (2S)-2-(TERT-BUTOXYCARBONYL)-AMINO-2-[-8-AZABICYCLO[3.2.1]OCT-3-YL]-EXO-ACETATE AND ANALOGS THEREOF: KEY INTERMEDIATES FOR THE PREPARATION OF DPPIV INHIBITORS | LUPIN LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
| US-20120203004-A1 | PROCESS FOR THE SYNTHESIS OF ALKYL/ARALKYL (2S)-2-(TERT-BUTOXYCARBONYL)-AMINO-2-[-8-AZABICYCLO[3.2.1]OCT-3-YL]-EXO-ACETATE AND ANALOGS THEREOF: KEY INTERMEDIATES FOR THE PREPARATION OF DPPIV INHIBITORS | LUPIN LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
| US-20120203004-A1 | PROCESS FOR THE SYNTHESIS OF ALKYL/ARALKYL (2S)-2-(TERT-BUTOXYCARBONYL)-AMINO-2-[-8-AZABICYCLO[3.2.1]OCT-3-YL]-EXO-ACETATE AND ANALOGS THEREOF: KEY INTERMEDIATES FOR THE PREPARATION OF DPPIV INHIBITORS | LUPIN LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
| WO-2009037719-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120203004-A1 | PROCESS FOR THE SYNTHESIS OF ALKYL/ARALKYL (2S)-2-(TERT-BUTOXYCARBONYL)-AMINO-2-[-8-AZABICYCLO[3.2.1]OCT-3-YL]-EXO-ACETATE AND ANALOGS THEREOF: KEY INTERMEDIATES FOR THE PREPARATION OF DPPIV INHIBITORS | DPP4, DPP8, DPP7 | SLC6A4 2348/4885SLC6A3 3736/4885SLC6A2 4023/4885 |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | DPP4, DPP7, DPP3 | SLC6A4 201/4885SLC6A3 258/4885SLC6A2 900/4885 |
| US-20170217974-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, ZC3HAV1, SLC10A1 | SLC6A4 4607/4885SLC6A3 4646/4885SLC6A2 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.